U.S. pharma big copyright scrapped two experimental weight loss capsules last calendar year—a after-every day tablet, lotiglipron, as a consequence of elevated liver enzymes plus a two times-daily capsule, danuglipron, as a consequence of robust Uncomfortable side effects—but CEO Albert Bourla has said the company is set to “Engage in and ear